抗PD-1/PD-L1免疫治疗生物标志物研究进展

Research progress of anti-PD-1/PD-L1 immunotherapy biomarkers

抗程序性死亡蛋白-1和程序性死亡蛋白配体-1(PD-L1)免疫检查点抑制剂已在多种实体瘤取得明显疗效,但是单药治疗有效率不高。因此,探寻合适的疗效预测标志物、精准选择潜在获益人群成为目前研究的热点。研究表明,PD-L1表达、肿瘤突变负荷、错配修复基因缺陷等可能与免疫治疗的疗效相关,对这些标志物的深入分析和探索可能为临床筛选免疫检查点抑制剂获益人群提供依据。

Immunological checkpoint inhibitors of anti-programmed cell death-1 and programmed cell death ligand-1(PD-L1)have already demonstrated remarkable clinical efficacy for solid tumors,however,the effectiveness of single drug therapy in immunotherapy is not very high.Therefore,exploring the appropriate therapeutic predictive biomarkers so as to accurately identify the potential patients suitable for this therapy has become a research hotspot.Studies have shown that biomarkers such as PD-L1,tumor mutation burden and mismatch repair deficiency may be related to the efficacy of immunotherapy.In-depth analysis and exploration of these markers may provide a basis for determining those patients who are more likely to benefit from checkpoint inhibitor.